Back to News
Market Impact: 0.38
Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth
Source: reuters.com
Healthcare & BiotechCorporate Guidance & OutlookCompany FundamentalsProduct Launches
Sandoz targets more than doubling net sales between 2025 and 2035 under its new Bio100 strategy. The Swiss drugmaker is shifting its focus from traditional generics toward biosimilars, positioning the company for longer-term growth in biologic-drug alternatives.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
SDZ0.65
More News
- 'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat
- European shares dip as higher crude revives inflation worries; Novartis drags
- Nvidia Earnings Blow Everyone Away
- China's EV makers shift gears to focus on humanoids as car market slows
- Chipotle's new restaurant in a hip Seoul neighborhood tests its Asian expansion strategy
- Apple's $2000+ iPhone, Oil Gain Stokes Inflation Fear | Bloomberg Businessweek Daily 9/8/2026